Patent intelligence · WO
WO 2026006232
COMPOSITION EFFERVESCENTE ORALE
COMPOSITION EFFERVESCENTE ORALE
Patent details — WO 2026006232
- Jurisdiction
- WO
- Status
- granted
- Grant date
- Jan 2, 2026
- Expiration
- Dec 28, 2045
- Applicant
- BAYER HEALTHCARE LLC [US]
- CPC classes
- A61K 9/ 20 A I, A61K 31/ 167 A I, A61K 31/ 485 A I, A61K 31/ 4402 A I
Quick answer
WO 2026006232 (COMPOSITION EFFERVESCENTE ORALE) is held by BAYER HEALTHCARE LLC [US]. Status: granted. Granted Jan 2, 2026. Expires Dec 28, 2045 (20 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- BAYER HEALTHCARE LLC [US]
- Grant date
- Expiration
- Claims
- —
- CPC classes
- A61K 9/ 20 A I, A61K 31/ 167 A I, A61K 31/ 485 A I, A61K 31/ 4402 A I, A61K/31167, A61K/314402
More from BAYER HEALTHCARE LLC [US]
Related pharmaceutical patents in our USPTO index.
-
WO 2026112109
TECHNOLOGIE DE PLATEFORME DE GRANULATION PAR VOIE HUMIDE POUR FABRIQUER DES COMPRIMÉS/ARTICLES À MÂCHER MOUS
granted -
WO 2026106858
FORMULATIONS ET PROCÉDÉS POUR MAINTENIR UNE SUSPENSION ET UNE VIABILITÉ DE CELLULES
granted -
EP 4741400
MULTIMERE MANGANKONTRASTMITTEL
granted -
WO 2026068294
PROCESSUS DE NANOENSEMENCEMENT AMÉLIORÉ
granted -
WO 2026047020
FORMES CRISTALLINES D'INHIBITEURS DE HER2/MUTEGFR ET LEUR PROCÉDÉ DE PRÉPARATION
granted -
WO 2026047022
FORME POSOLOGIQUE PHARMACEUTIQUE SOLIDE ET STABLE COMPRENANT UNE FORME CRISTALLINE D'UN INHIBITEUR DE HER2/MUTEGFR ET SA MÉTHODE DE PRÉPARATION
granted -
US 20260051027
GENERATION OF SYNTHETIC CONTRAST-ENHANCED RADIOLOGICAL IMAGES
granted -
WO 2026032865
SEL D'UN INHIBITEUR DE SOS-1
granted
Frequently asked questions
What is US patent 2026006232?
WO 2026006232 (COMPOSITION EFFERVESCENTE ORALE) is held by BAYER HEALTHCARE LLC [US]. Status: granted. Granted Jan 2, 2026. Expires Dec 28, 2045 (20 years remaining) — relevant for patent-cliff and LOE planning.
Who owns WO 2026006232?
BAYER HEALTHCARE LLC [US] is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 25 pharmaceutical patents for this assignee.
When does WO 2026006232 expire?
Our index shows an expiration date of Dec 28, 2045 (20 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.